Aravive Inc. (ARAV) PT Raised to $31 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St indexes eye weekly losses; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Aravive Inc. (ARAV) PT Raised to $28 at Wedbush
November 20, 2019 12:12 PM ESTWedbush analyst David Nierengarten raised the price target on Aravive Inc. (NASDAQ: ARAV) to $28.00 (from $12.00) while maintaining a Outperform rating.
... MoreAravive Inc. (ARAV) PT Raised to 'Street High' $36 at Piper Jaffray
November 20, 2019 10:34 AM ESTPiper Jaffray analyst Edward Tenthoff raised the price target on Aravive Inc. (NASDAQ: ARAV) to $36.00 (from $15.00) while maintaining a Overweight rating.
... MoreAravive Inc. (ARAV) Halted on LUDP
November 20, 2019 9:46 AM ESTAravive Inc. (NASDAQ: ARAV) Halted on LUDP
... MorePre-Open 11/20: (ARAV) (I) (TGT) Higher (PDD) (URBN) (MUX) Lower (more...)
November 20, 2019 9:16 AM ESTToday's Pre-Open Movers
Aravive, Inc. (Nasdaq: ARAV) 214.9% HIGHER; announced new positive data from the ongoing Phase 1b portion of the Phase 1b/2 clinical trial of AVB-500 in platinum-resistant recurrent ovarian cancer patients. The data from the first 31 patients treated at the 10mg/kg dose are maturing and affirm earlier findings on the relationship between AVB-500 levels and anti-tumor response. In this data analysis, high serum drug levels of AVB-500 were strongly predictive of anti-tumor activity with statistically significant correlation to progression-free survival (PFS; p=0.0066). PFS is the primary endpoint for... More
Aravive Inc. (ARAV) Extends Gain, Up 250%
November 20, 2019 7:43 AM ESTAravive Inc. (NASDAQ: ARAV) Extends Gain, Up 250%
Aravive Inc. (ARAV) Climbs 80% After Positive Data from Ongoing Trial of AVB-500 in Ovarian Cancer
November 20, 2019 7:21 AM ESTAravive Inc. (NASDAQ: ARAV) Climbs 80% After Positive Data from Ongoing Trial of AVB-500 in Ovarian Cancer
... MoreAravive (ARAV) Reports Positive Data Supporting Relationship Between AVB-500 Levels, Anti-Tumor Activity and Progression Free Survival in Women with Ovarian Cancer
November 20, 2019 7:02 AM ESTAravive, Inc. (Nasdaq: ARAV) today announced new positive data from the ongoing Phase 1b portion of the Phase 1b/2 clinical trial of AVB-500 in platinum-resistant recurrent ovarian cancer patients. The data from the first 31 patients treated at the 10mg/kg dose are maturing and affirm earlier findings on the relationship between AVB-500 levels and anti-tumor response. In this data analysis, high serum drug levels of AVB-500 were strongly predictive of anti-tumor activity with statistically significant correlation to progression-free survival (PFS; p=0.0066). PFS is the primary endpoint for platinum-resistant ovarian cancer clinical... More
